M Hiragun1, T Hiragun, S Mihara, T Akita, J Tanaka, M Hide. 1. Department of Dermatology, Integrated Health Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima.
Abstract
BACKGROUND: Chronic spontaneous urticaria (CSU) is a common skin disorder, but its clinical course reported so far is largely variable, probably due to the heterogeneity of the clinical background of patients and pathogenesis of this disease. METHODS: To reveal the prognosis of refractory CSU, we retrospectively studied the patients who suffered from spontaneous urticaria for six weeks or longer at their first visit to our outpatient clinic, who were insufficiently controlled by a standard dose of antihistamine, and revisited from 2003 to 2009. RESULTS: Among 223 patients with CSU, 117 patients fulfilled the criteria mentioned above. Mean disease duration at first visit and mean duration of follow-up at our hospital were 27.4 ± 4.2 months and 18.7 ± 1.9 months, respectively. By using Kaplan-Meier methods, the estimated improved rates at 12 months, 24 months, and 60 months were 36.6%, 51.2%, and 66.1%, respectively. The overall improvement rate of childhood cases (<19 years) was significantly higher than that of adult cases (P = 0.007, log-rank test). Moreover, the improvement rate of patients with short disease durations (<1 year at the first visit) was significantly (P = 0.003, log-rank test) higher than that of patients with long disease durations (one year or more). CONCLUSION: Our data indicate that the condition of patients with CSU can be gradually improved even in intractable cases. Information about the clinical course and prognostic factors of CSU in this study could help physicians predict the prognosis of patients and ensure medication adherence of patients with CSU.
BACKGROUND: Chronic spontaneous urticaria (CSU) is a common skin disorder, but its clinical course reported so far is largely variable, probably due to the heterogeneity of the clinical background of patients and pathogenesis of this disease. METHODS: To reveal the prognosis of refractory CSU, we retrospectively studied the patients who suffered from spontaneous urticaria for six weeks or longer at their first visit to our outpatient clinic, who were insufficiently controlled by a standard dose of antihistamine, and revisited from 2003 to 2009. RESULTS: Among 223 patients with CSU, 117 patients fulfilled the criteria mentioned above. Mean disease duration at first visit and mean duration of follow-up at our hospital were 27.4 ± 4.2 months and 18.7 ± 1.9 months, respectively. By using Kaplan-Meier methods, the estimated improved rates at 12 months, 24 months, and 60 months were 36.6%, 51.2%, and 66.1%, respectively. The overall improvement rate of childhood cases (<19 years) was significantly higher than that of adult cases (P = 0.007, log-rank test). Moreover, the improvement rate of patients with short disease durations (<1 year at the first visit) was significantly (P = 0.003, log-rank test) higher than that of patients with long disease durations (one year or more). CONCLUSION: Our data indicate that the condition of patients with CSU can be gradually improved even in intractable cases. Information about the clinical course and prognostic factors of CSU in this study could help physicians predict the prognosis of patients and ensure medication adherence of patients with CSU.
Authors: M Ferrer; J Bartra; A Giménez-Arnau; I Jauregui; M Labrador-Horrillo; J Ortiz de Frutos; J F Silvestre; J Sastre; M Velasco; A Valero Journal: Clin Exp Allergy Date: 2015-04 Impact factor: 5.018
Authors: Mario Sánchez-Borges; Ignacio Ansotegui; Jorge Montero Jimenez; Maria Isabel Rojo; Carlos Serrano; Anahí Yañez Journal: World Allergy Organ J Date: 2014-11-26 Impact factor: 4.084
Authors: Yoon Seob Kim; Sang Hyun Park; Kyungdo Han; Ji Hyun Lee; Nack In Kim; Joo Young Roh; Seong Jun Seo; Hae Jun Song; Min Geol Lee; Jee Ho Choi; Young Min Park Journal: Allergy Asthma Immunol Res Date: 2018-01 Impact factor: 5.764
Authors: Young Min Ye; Jung Won Park; Sang Ha Kim; Ga Young Ban; Ji Hye Kim; Yoo Seob Shin; Hyun Young Lee; Hae Sim Park Journal: Allergy Asthma Immunol Res Date: 2015-11-10 Impact factor: 5.764